Welcome to our dedicated page for Inflarx SEC filings (Ticker: IFRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to InflaRx N.V. (Nasdaq: IFRX) SEC filings, where the company discloses financial results, clinical updates and key corporate information as a foreign private issuer. InflaRx files annual reports on Form 20-F and current reports on Form 6-K that include unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and detailed descriptions of clinical and regulatory developments.
Through these filings, readers can review how InflaRx reports progress with its complement-focused pipeline, including the oral C5a receptor inhibitor izicopan (INF904) and the anti-C5a monoclonal antibody vilobelimab. Selected 6-K reports incorporate press releases and presentations on Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, analyses of Phase 3 data in pyoderma gangrenosum, and updates on BARDA-supported studies in acute respiratory distress syndrome.
InflaRx’s SEC filings also document matters such as changes in independent auditors, notices from Nasdaq regarding minimum bid price requirements and subsequent compliance, and information about collaboration arrangements, including royalty-bearing rights related to the anti-C5a antibody BDB-001 in China. Financial sections outline revenues, research and development expenses, sales and marketing costs, general and administrative expenses, cash balances and financing activities.
On Stock Titan, InflaRx filings are updated as new documents are released on EDGAR. AI-powered tools can help summarize lengthy 20-F and 6-K reports, highlight key points about IFRX’s clinical programs, and surface information on risk factors, liquidity and capital resources. Users interested in insider or major shareholder activity can complement these filings with ownership and transaction data where available, while relying on the filings themselves for the company’s official narrative on its complement-system therapeutic strategy and financial position.
InflaRx N.V. is restructuring to cut costs and focus on its lead oral C5aR inhibitor, izicopan (INF904), in hidradenitis suppurativa (HS) and other inflammation and immunology indications. The company is reducing spending, shifting resources away from non-essential activities and emphasizing izicopan’s development and potential “pipeline-in-a-product” profile.
InflaRx is implementing an approximate 30% workforce reduction and other spending cuts, including significant reductions in Gohibic (vilobelimab) commercial activities. These actions are expected to lead to a one-time charge of about $7 million, largely from a non-cash vilobelimab inventory write-off, and to materially lower ongoing operating expenses while extending the cash runway to mid-2027.
The company will maintain capabilities to support the BARDA-sponsored Phase 2 “Just Breathe” ARDS study and keep Gohibic available under its U.S. emergency use authorization. It continues to seek partners for Gohibic, plan discussions with the FDA on vilobelimab in pyoderma gangrenosum, and advance izicopan in HS and chronic spontaneous urticaria, including closing a low-enrollment CSU cohort, preparing further clinical plans, and organizing a virtual capital markets day to detail izicopan’s clinical and commercial potential.
InflaRx N.V. (IFRX) reported preliminary, positive Phase 2a topline results for INF904, an oral C5aR inhibitor, in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study evaluated safety and PK/PD with exploratory efficacy.
In HS (efficacy n=29 of 31; safety n=33), patients showed rapid, clinically meaningful reductions in abscesses and nodules and draining tunnels, improved pain (NRS30) and DLQI, and higher HiSCR at end of treatment that continued to deepen four weeks later. The company notes these 4‑week outcomes were largely in line with similar timepoint data from approved HS therapies. No serious adverse events were reported across doses (60, 90, 120 mg BID).
In CSU (efficacy n=30 of 31; safety n=33), the 60 mg BID cohort achieved a UAS7 change from baseline of -13.7 at week 4, exceeding average historically reported placebo levels and generally within the range of existing approved CSU drugs. Severe CSU at baseline saw a -15.4 UAS7 change; patients with angioedema at baseline saw -18.7. Improvements began by Week 1 and generally deepened over the four-week treatment period. No serious adverse events were reported.
FAQ
What is the current stock price of Inflarx (IFRX)?
What is the market cap of Inflarx (IFRX)?
